We are attending EHA2023, 8-11th June in Frankfurt. Meet us at the EHA2023 Hybrid Congress in Frankfurt and find out more.

At the Menarini Group, we’re committed to making a difference in patients’ lives with specific hematologic malignancies and those with significant unmet medical needs.

EHA2023 will provide a platform to engage and network with clinical professionals and thought leaders – potentially leading to collaborative initiatives with common goals of furthering our understanding about hematologic malignancies, improving patient outcomes through early detection and the development of precision medicines.

Join us to discuss the unmet medical needs of patients with Multiple Myeloma and BPDCN.  

We look forward to meeting with you in Frankfurt! Visit us at Booth 104: https://ehaweb.org/congress/eha2023-hybrid-congress/program/program-by-day/

Unmet need in multiple myeloma

Multiple myeloma is the second most common hematologic malignancy globally, and to date remains incurable with significant morbidity. Data from Globocan reported that in 2020 almost 51,000 new cases and 32,000 deaths from multiple myeloma occurred in Europe. The treatment of multiple myeloma has improved over time and overall survival has increased considerably, however, nearly all patients will eventually relapse and develop disease that is refractory to anti-myeloma therapies. Consequently, only 15% of patients are reported to reach fourth line therapy and beyond. Therefore, there continues to be a high unmet medical need for new therapies, particularly those with novel mechanisms of action.

Unmet need in BPDCN

BPDCN, formerly known as blastic natural killer cell lymphoma, is an aggressive hematologic malignancy, often presenting with cutaneous manifestations, with poor outcomes. It typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera and originates in plasmacytoid dendritic precursor cells. However, its similarity to other hematologic malignancies, including those with skin manifestations (e.g. acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia), and its frequent reclassification and renaming have likely contributed to it being commonly misdiagnosed. The diagnosis of BPDCN is now based on the immunophenotypic diagnostic triad of CD123, CD4, and CD56, as well as other markers. In these patients there is an unmet need for faster and more accurate diagnosis, and for new therapeutic options. Currently, treatment recommendations vary by location, availability of therapies and physician experience.